Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2020-12, Vol.50 (12), p.1998-2012
Hauptverfasser: Oja, Anna E., Saris, Anno, Ghandour, Cherien A., Kragten, Natasja A.M., Hogema, Boris M., Nossent, Esther J., Heunks, Leo M.A., Cuvalay, Susan, Slot, Ed, Linty, Federica, Swaneveld, Francis H., Vrielink, Hans, Vidarsson, Gestur, Rispens, Theo, Schoot, Ellen, Lier, René A.W., Ten Brinke, Anja, Hombrink, Pleun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2012
container_issue 12
container_start_page 1998
container_title European journal of immunology
container_volume 50
creator Oja, Anna E.
Saris, Anno
Ghandour, Cherien A.
Kragten, Natasja A.M.
Hogema, Boris M.
Nossent, Esther J.
Heunks, Leo M.A.
Cuvalay, Susan
Slot, Ed
Linty, Federica
Swaneveld, Francis H.
Vrielink, Hans
Vidarsson, Gestur
Rispens, Theo
Schoot, Ellen
Lier, René A.W.
Ten Brinke, Anja
Hombrink, Pleun
description Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients. T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.
doi_str_mv 10.1002/eji.202048908
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452096353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2452096353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</originalsourceid><addsrcrecordid>eNp9kbtOw0AQRVcIBCFQ0qKVaGgMs6_EW0J4BSFF4pHWctZjtJFjG68NouMT-Ea-hIkSKCgoZmdWOrqaO5exAwEnAkCe4tyfSJCgYwvxBusJI0WkhRabrAcgdCRtDDtsN4Q5ANiBsdtsRykYKmVsj80v_Cs2z1i2_OHs_uHr43NUTemVVKFG53Pv-CN9eFpm_JwGh0XBGwx1VQYM3Jc8IEkgn3UtL6uWL3yR8dFkOr4gWlhep60n_bDHtvK0CLi_7n32dHX5OLqJ7ibX49HZXeS0EiLKldXWSQcKtbEiiwcAwzwXOMiz1GRWZWSRIJE6K0XsjLZk32UzMTMWjFZ9drzSrZvqpcPQJgsfllunJVZdSKQ2kg6hjCL06A86r7qmpO2IGliwVmkgKlpRrqlCaDBP6sYv0uY9EZAsQ0gohOQ3BOIP16rdbIHZL_1zdQLkCnjzBb7_r5Zc3o41GVXfyD6T8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2469099340</pqid></control><display><type>article</type><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</creator><creatorcontrib>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients. T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</description><identifier>ISSN: 0014-2980</identifier><identifier>EISSN: 1521-4141</identifier><identifier>DOI: 10.1002/eji.202048908</identifier><identifier>PMID: 33073359</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Antibodies, Viral - immunology ; Antibody response ; B-Lymphocytes - immunology ; B-Lymphocytes - pathology ; CD4 antigen ; CD4+ T cells ; CD4-Positive T-Lymphocytes - immunology ; CD4-Positive T-Lymphocytes - pathology ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; COVID-19 - pathology ; Female ; Humans ; IgG ; Immunoglobulin G ; Immunoglobulin G - immunology ; Lymphocytes T ; Male ; Middle Aged ; Pandemics ; SARS-CoV-2 - immunology ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; Severity of Illness Index</subject><ispartof>European journal of immunology, 2020-12, Vol.50 (12), p.1998-2012</ispartof><rights>2020 Wiley‐VCH GmbH</rights><rights>2020 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</citedby><cites>FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</cites><orcidid>0000-0002-9433-1630 ; 0000-0001-9600-1312</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feji.202048908$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feji.202048908$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33073359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oja, Anna E.</creatorcontrib><creatorcontrib>Saris, Anno</creatorcontrib><creatorcontrib>Ghandour, Cherien A.</creatorcontrib><creatorcontrib>Kragten, Natasja A.M.</creatorcontrib><creatorcontrib>Hogema, Boris M.</creatorcontrib><creatorcontrib>Nossent, Esther J.</creatorcontrib><creatorcontrib>Heunks, Leo M.A.</creatorcontrib><creatorcontrib>Cuvalay, Susan</creatorcontrib><creatorcontrib>Slot, Ed</creatorcontrib><creatorcontrib>Linty, Federica</creatorcontrib><creatorcontrib>Swaneveld, Francis H.</creatorcontrib><creatorcontrib>Vrielink, Hans</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Schoot, Ellen</creatorcontrib><creatorcontrib>Lier, René A.W.</creatorcontrib><creatorcontrib>Ten Brinke, Anja</creatorcontrib><creatorcontrib>Hombrink, Pleun</creatorcontrib><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><title>European journal of immunology</title><addtitle>Eur J Immunol</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients. T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibody response</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - pathology</subject><subject>CD4 antigen</subject><subject>CD4+ T cells</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD4-Positive T-Lymphocytes - pathology</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>IgG</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - immunology</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Severity of Illness Index</subject><issn>0014-2980</issn><issn>1521-4141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kbtOw0AQRVcIBCFQ0qKVaGgMs6_EW0J4BSFF4pHWctZjtJFjG68NouMT-Ea-hIkSKCgoZmdWOrqaO5exAwEnAkCe4tyfSJCgYwvxBusJI0WkhRabrAcgdCRtDDtsN4Q5ANiBsdtsRykYKmVsj80v_Cs2z1i2_OHs_uHr43NUTemVVKFG53Pv-CN9eFpm_JwGh0XBGwx1VQYM3Jc8IEkgn3UtL6uWL3yR8dFkOr4gWlhep60n_bDHtvK0CLi_7n32dHX5OLqJ7ibX49HZXeS0EiLKldXWSQcKtbEiiwcAwzwXOMiz1GRWZWSRIJE6K0XsjLZk32UzMTMWjFZ9drzSrZvqpcPQJgsfllunJVZdSKQ2kg6hjCL06A86r7qmpO2IGliwVmkgKlpRrqlCaDBP6sYv0uY9EZAsQ0gohOQ3BOIP16rdbIHZL_1zdQLkCnjzBb7_r5Zc3o41GVXfyD6T8Q</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Oja, Anna E.</creator><creator>Saris, Anno</creator><creator>Ghandour, Cherien A.</creator><creator>Kragten, Natasja A.M.</creator><creator>Hogema, Boris M.</creator><creator>Nossent, Esther J.</creator><creator>Heunks, Leo M.A.</creator><creator>Cuvalay, Susan</creator><creator>Slot, Ed</creator><creator>Linty, Federica</creator><creator>Swaneveld, Francis H.</creator><creator>Vrielink, Hans</creator><creator>Vidarsson, Gestur</creator><creator>Rispens, Theo</creator><creator>Schoot, Ellen</creator><creator>Lier, René A.W.</creator><creator>Ten Brinke, Anja</creator><creator>Hombrink, Pleun</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9433-1630</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid></search><sort><creationdate>202012</creationdate><title>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</title><author>Oja, Anna E. ; Saris, Anno ; Ghandour, Cherien A. ; Kragten, Natasja A.M. ; Hogema, Boris M. ; Nossent, Esther J. ; Heunks, Leo M.A. ; Cuvalay, Susan ; Slot, Ed ; Linty, Federica ; Swaneveld, Francis H. ; Vrielink, Hans ; Vidarsson, Gestur ; Rispens, Theo ; Schoot, Ellen ; Lier, René A.W. ; Ten Brinke, Anja ; Hombrink, Pleun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4311-f3949c2c03e4591d86007ff1e6fda5d93d152f391ac9218c549020cdb1b590543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibody response</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - pathology</topic><topic>CD4 antigen</topic><topic>CD4+ T cells</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD4-Positive T-Lymphocytes - pathology</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>IgG</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - immunology</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oja, Anna E.</creatorcontrib><creatorcontrib>Saris, Anno</creatorcontrib><creatorcontrib>Ghandour, Cherien A.</creatorcontrib><creatorcontrib>Kragten, Natasja A.M.</creatorcontrib><creatorcontrib>Hogema, Boris M.</creatorcontrib><creatorcontrib>Nossent, Esther J.</creatorcontrib><creatorcontrib>Heunks, Leo M.A.</creatorcontrib><creatorcontrib>Cuvalay, Susan</creatorcontrib><creatorcontrib>Slot, Ed</creatorcontrib><creatorcontrib>Linty, Federica</creatorcontrib><creatorcontrib>Swaneveld, Francis H.</creatorcontrib><creatorcontrib>Vrielink, Hans</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Schoot, Ellen</creatorcontrib><creatorcontrib>Lier, René A.W.</creatorcontrib><creatorcontrib>Ten Brinke, Anja</creatorcontrib><creatorcontrib>Hombrink, Pleun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oja, Anna E.</au><au>Saris, Anno</au><au>Ghandour, Cherien A.</au><au>Kragten, Natasja A.M.</au><au>Hogema, Boris M.</au><au>Nossent, Esther J.</au><au>Heunks, Leo M.A.</au><au>Cuvalay, Susan</au><au>Slot, Ed</au><au>Linty, Federica</au><au>Swaneveld, Francis H.</au><au>Vrielink, Hans</au><au>Vidarsson, Gestur</au><au>Rispens, Theo</au><au>Schoot, Ellen</au><au>Lier, René A.W.</au><au>Ten Brinke, Anja</au><au>Hombrink, Pleun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients</atitle><jtitle>European journal of immunology</jtitle><addtitle>Eur J Immunol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>50</volume><issue>12</issue><spage>1998</spage><epage>2012</epage><pages>1998-2012</pages><issn>0014-2980</issn><eissn>1521-4141</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS‐CoV‐2‐specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T‐cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T‐cell compartment, and indicative of vascular leakage. The observed disparate T‐ and B‐cell responses could be indicative of a deregulated immune response in critically ill COVID‐19 patients. T‐ and B‐cell responses are misbalanced in critically ill COVID‐19 patients compared to patients with mild or severe symptoms. CD4+ T‐cell responses in these patients are impaired qualitatively and quantitatively. BALF of ICU patients shows an influx of circulating T cells indicative of vascular leakage and lung damage.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33073359</pmid><doi>10.1002/eji.202048908</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-9433-1630</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-2980
ispartof European journal of immunology, 2020-12, Vol.50 (12), p.1998-2012
issn 0014-2980
1521-4141
language eng
recordid cdi_proquest_miscellaneous_2452096353
source MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection)
subjects Adult
Aged
Antibodies, Viral - immunology
Antibody response
B-Lymphocytes - immunology
B-Lymphocytes - pathology
CD4 antigen
CD4+ T cells
CD4-Positive T-Lymphocytes - immunology
CD4-Positive T-Lymphocytes - pathology
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - pathology
Female
Humans
IgG
Immunoglobulin G
Immunoglobulin G - immunology
Lymphocytes T
Male
Middle Aged
Pandemics
SARS-CoV-2 - immunology
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
Severity of Illness Index
title Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T05%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Divergent%20SARS%E2%80%90CoV%E2%80%902%E2%80%90specific%20T%E2%80%90%20and%20B%E2%80%90cell%20responses%20in%20severe%20but%20not%20mild%20COVID%E2%80%9019%20patients&rft.jtitle=European%20journal%20of%20immunology&rft.au=Oja,%20Anna%20E.&rft.date=2020-12&rft.volume=50&rft.issue=12&rft.spage=1998&rft.epage=2012&rft.pages=1998-2012&rft.issn=0014-2980&rft.eissn=1521-4141&rft_id=info:doi/10.1002/eji.202048908&rft_dat=%3Cproquest_cross%3E2452096353%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2469099340&rft_id=info:pmid/33073359&rfr_iscdi=true